Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase I/II Study of the Oral RET inhibitor LOXO 292 in Paediatric patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours
Protocol ID
LOXO-RET-18036
Disease (Sub Disease)
Brain and Spinal Tumours
Diagnosis Stage
Relapse/ refractory
Location
NSW, VIC
Sponsor
Loxo Oncology, Inc.
Collaborators
Eli Lilly and Company
Links
Trial Status
Open
Sites
Sydney Children's Hospital
Royal Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
6 months to 21 years
International registry ID's
NCT03899792
| Study Title | A Phase I/II Study of the Oral RET inhibitor LOXO 292 in Paediatric patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours |
|---|---|
| Protocol ID | LOXO-RET-18036 |
| Disease (Sub Disease) | Brain and Spinal Tumours |
| Diagnosis Stage | Relapse/ refractory |
| Location | NSW / VIC |
| Sponsor | Loxo Oncology, Inc. |
| Collaborators | Eli Lilly and Company |
| Links | https://clinicaltrials.gov/ct2/show/NCT03899792 |
| Trial Status | Open |
| Trial Open Date | 01/07/2019 |
| Sites | Sydney Children's Hospital / Royal Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 6 months to 21 years |
| International registry ID's | NCT03899792 |